Altus Biologics Inc. was awarded a $300,000 Phase II SmallBusiness Innovation Research grant to expand development and usesof its Cross-Linked Enzyme Crystals (CLECs) technology.The two-year grant will cover optimization of lipases and esterases,two classes of enzymes used in the manufacture of valued-addedproducts such as fine chemicals and chiral pharmaceuticals. Underthe grant, the Cambridge, Mass., company also will perform studiesdocumenting the ability of CLEC lipases and esterases to remainstable and active in harsh environments encountered in industrialapplications that destroy conventional biocatalysts.

(c) 1997 American Health Consultants. All rights reserved.